---
title: "BioHarvest Sciences Inc. (BHST.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/BHST.US.md"
symbol: "BHST.US"
name: "BioHarvest Sciences Inc."
industry: "Personal Care Products"
---

# BioHarvest Sciences Inc. (BHST.US)

| Item | Detail |
|------|--------|
| Industry | Personal Care Products |
| Location | US Market |
| Website | [www.bioharvest.com](https://www.bioharvest.com) |

## Company Profile

BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through Nutraceuticals and Pharmaceuticals segments. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients.

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-03-01T04:30:14.000Z

**Overall: C (0.46)**

**Industry**: Personal Care Products

| Metric | Value |
|--------|-------|
| Industry Ranking | 27 / 58 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 45.88% |  |
| Net Profit YoY | 30.86% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 13.79 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 106.70M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 32.72M |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -200.22% | E |
| Profit Margin | -36.33% | E |
| Gross Margin | 61.43% | A |

#### Growth Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 45.88% | A |
| Net Profit YoY | 30.86% | B |
| Total Assets YoY | 36.27% | A |
| Net Assets YoY | 86.88% | A |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -275.26% | D |
| OCF YoY | 45.88% | A |

#### Operating Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 1.07 | A |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 78.02% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - BioHarvest Sciences Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-200.22%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-36.33%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "61.43%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "A",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "45.88%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "30.86%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "36.27%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "86.88%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-275.26%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "45.88%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "A",
      "indicators": [
        {
          "name": "Turnover",
          "value": "1.07",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "78.02%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Niagen Bioscience (US.NAGE) | A | A | A | B | B | A |
| 02 | L'Oréal S.A. (US.LRLCY) | A | B | B | C | B | B |
| 03 | Beiersdorf (US.BDRFY) | B | C | B | B | B | B |
| 04 | Kao Corporation (US.KAOOY) | B | C | A | C | B | B |
| 05 | ELF Beauty (US.ELF) | B | B | B | C | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -8.98 | 37/56 | - | - | - |
| PB | 13.79 | 40/56 | 73.09 | 18.57 | 14.67 |
| PS (TTM) | 3.26 | 39/56 | 5.14 | 4.38 | 3.81 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-19T05:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 3 | 75% |
| Overweight | 1 | 25% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.71 |
| Highest Target | 15.00 |
| Lowest Target | 10.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/BHST.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/BHST.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/BHST.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.